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Poster Session-II 153Pediatric hematopoietic stem cell transplantation (HSCT) is
a lengthy, dynamic and complex medical procedure requiring multi-
ple invasive procedures. Although the procedure is accepted to treat
and ameliorate a variety of medical conditions, the process has dele-
terious physiological and psychological consequences. One of the
more common medical problems experienced by HSCT patients is
pain. Causes of pain in this patient population are multi-factorial,
but frequently can be attributable to conditioning regimen-related
toxicities (e.g., mucositis), medical procedures (e.g., catheter inser-
tions), and medication administration (e.g., subcutaneous injections).
As a result, the pain experienced by HSCT recipients significantly
and adversely impacts their medical course, performance status and
quality of life as well as the quality of life of those around them. Ef-
forts to lessen the duration and decrease the intensity of pain experi-
enced by children undergoingHSCT are crucial to successful patient
outcomes and improved quality of life. We have implemented one
method to address an aspect of this medical need through the use
of an indwelling catheter (insuflone; manufactured by Unomedical,
Denmark) as a means of administering subcutaneous medications.
Prior to the initiation of therapies administered subcutaneously, an
insuflon catheter is placed by the nurse. Training for catheter place-
ment is straightforward and can be accomplished within 30 minutes
using a preceptor model. The catheter is allowed to remain in place
for up to seven days and avoids daily insertion of a needle into the sub-
cutaneous tissue to deliver prescribed medications. We will summa-
rize our experience with using insuflon catheters in HSCT patients
for the administration of Neupogen (filgrastim) and Lovenox
(enoxaparin). Educational materials for health care professionals as
well as for patients and their caregivers will be presented. Addition-
ally, as a result of our success with insuflon catheters in our HSCT
recipients, policies and procedures for expanding the use of this cath-
eter to other patient populations as well as for the administration of
additional agents will be shared. This information is expected to be
of widespread interest since by decreasing the pain and anxiety sur-
rounding daily subcutaneous injections we have positively impacted
the quality of life of patients and care givers as well as strengthened
the healthcare professional-patient relationship.PHARMACY435
EFFICACY OF PALIFERMIN FOR MUCOSITIS IN HEMATOPOIETIC STEM
CELL TRANSPLANT RECIPIENTS
Campaign, J.E.1, Ippoliti, C.2 1 University of New Mexico, Albuquerque,
NM; 2 NewYork-Presbyterian Hospital Weill Cornell Medical College,
New York, NY
Palifermin is recommended by the American Cancer Society to re-
duce the incidence and severity of mucositis in patients undergoing
high-dose chemotherapy with total body irradiation (TBI) prior to
autologous stemcell transplant (SCT). Since approval, results of stud-
ies of palifermin have been mixed. This study was undertaken to de-
termine the impact of palifermin on the incidence and severity of
mucositis in a high-risk population of SCT recipients who received
a variety of conditioning regimens at a large teaching institution.
We retrospectively compared outcomes of 18 palifermin-treated
SCT recipients with those of 33 patients managed prior to palifermin
availability. Paliferminwasdosed 60micrograms/kg/day IV for 3 days
prior to chemotherapy and 3 days after stem cell infusion. Controls
were matched based on type of malignancy, preparative regimen,
and high-risk features (dialysis, CrCl \60 mL/min, Karnofsky
performance score\70, allogeneic stem cell source). All patients re-
ceived peripheral stem cells, and 16.7% of palifermin patients and
18.2% of controls received those from an allogeneic source. Multiple
myeloma was the most common diagnosis, and melphalan was the
most common conditioning agent (both 76.4%).Only 11%of palifer-
min patients and 12.1%of controls received TBI.Median duration of
mucositis was 17 (3–42) days for palifermin patients vs. 12 (4–41) days
for controls (p 5 0.06). A total of 66.7% of palifermin patients vs.
51.5% of controls experienced grade 3–4 mucositis (p 5 0.38), for
a median duration of 9 (4–33) vs. 7 (3–18) days, respectively (p 5
0.05). Palifermin-treated patients did not experience a shortermedian
length of stay, and there was no significant difference in duration of
opioid or parenteral nutrition use. Based on these findings, palifermindoes not appear to provide significant benefit in the SCT population
at this institution to justify its cost. Further research is warranted to
determine under which conditions palifermin provides positive
outcomes.436
EVALUATING CLINICAL PHARMACY SERVICES IN A LEUKEMIA/BMT MED-
ICAL INTERVENTION CLINIC: A PILOT PROJECT
Warkentin, D.I.1, Lacaria, K.1, Partovi, N.1, Berryman, K.1, Smith, C.2
1 Vancouver Coastal Health, Vancouver, BC, Canada; 2 BC Cancer
Agency, Vancouver, BC, Canada
Introduction: There has been a significant increase in the number
of patients requiring either chemotherapy or HSCT being treated as
outpatients at the Leukemia/BMT Program of B.C. These patients
are complex medically and are on a greater number of medications.
Clinical pharmacy services are provided to the inpatient Leukemia/
BMT unit but not the outpatient clinic. Various studies have demon-
strated that the provision of clinical pharmacy services can significantly
reduce the occurrence of adverse drug events and improve patient
outcomes. Also the availability of clinical pharmacists can reduce the
occurrence of medication errors and significantly reduce drug costs,
thought the promotion of rational and cost effective medication use.
Main Thesis: The Leukemia/BMT Outpatient clinic received
full time clinical pharmacist for a six-month trial. During this evalu-
ation period and as part of quality improvement efforts by pharmacy
administration, services have been documented manually and by
using a personal digital assistant (PDA). Data fields as described by
Hepler and Strand, currently used in the inpatient unit, were used
and all other interventions were documented manually1. Interven-
tions were categorized into the following: patient access, patient
safety, cost containment, improved quality of patient care, reduced
workload and improved staff morale. SUMMARY This is the first
Canadian study to document considerable contributions of a clinical
pharmacy in an outpatient leukemia/HSCT clinic providing direct
patient care. These findings indicate clinical pharmacy services are
essential in providing quality patient care in an outpatient setting.
Conclusion: Permanent funding for a clinical pharmacist in the
Outpatient Leukemia/BMT Program is justified.437
SUBCUTANEOUS ADMINISTRATION OF ALEMTUZUMAB (CAMPATH-1H)
IS WELL TOLERATED AND EFFECTIVE
Lawrence, J., Bleesing, J., Filipovich, A., Jodele, S., Mehta, P., Davies, S.
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Alemtuzumab (campath-1H) is a humanized anti-CD52monoclo-
nal antibody that has been successfully used as part of conditioning
regimes for HSCT to prevent GVHD. Intravenous alemtuzumab
is associated with frequent infusion related toxicity. We hypothe-
sized that subcutaneous alemtuzumab would be better tolerated
and effective. We have treated 32 patients receiving HSCT for
mainly non-malignant diseases with a reduced-intensity preparatory
regime including campath-1H, fludarabine, and melphalan. Sixteen
patients were given intravenous alemtuzumab, 14 subcutaneous
alemtuzumab and 2 a combination of 2 doses subcutaneous alemtu-
zumab followed by 2 doses of intravenous alemtuzumab. Fifteen pa-
tients had immune deficiency diseases, 6 metabolic disorders, 6
HLH, 3 Schwachman Diamond syndrome, 1 Kostmann’s syndrome
and 1 MDS. Age range was 4 months to 15 years. All patients re-
ceived bone marrow except one cord blood. Twenty seven donors
were unrelated, 4 matched siblings, and 1 unrelated donor umbilical
cord. Patients who received subcutaneous or intravenous alemtuzu-
mab showed similar drops in lymphocyte counts at Day15 and Day
17 after alemtuzumab. Thirteen of 16 patients receiving intravenous
alemtuzumab had fever associated with administration, 10 had rash
and 11 reported other toxicities as rigors, chills, hives, pruritus,
tachycardia, hypotension, nausea, vomiting, and headache. In the
group receiving subcutaneous alemtuzumab, 7 of 16 developed fe-
vers, 2 developed rash and 3 reported other toxicities as nausea,
chills, and tachycardia. The incidence of GVHD was similar in the
two groups, 5 of 16 in the intravenous group and 8 of 16 in the sub-
cutaneous group. Survival was similar in the two groups, with 16 of
18 surviving at day 100 in the intravenous group and 15 of 16 in the
154 Poster Session-IIsubcutaneous group.We conclude that subcutaneous administration
of alemtuzumab shows similar outcomes as intravenous administra-
tion in the reduced intensity preparatory regime for non-malignant
diseases with less toxicity to the patient.438
USE OF A CALCIUM/PHOSPHATE ORAL RINSE (CAPHOSOLR) TO LESSEN
THE MUCOSITIS FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION
Bechtel, T.P.1, Devine, S.2 1 Arthur G James Cancer Hospital and Richard
J Solove Research Institute at the Ohio State University Medical Center,
Columbus, OH; 2 Arthur G James Cancer Hospital and Richard J Solove
Research Institute at the Ohio State University Medical Center, Columbus,
OH
The high-dose chemotherapy/radiation therapy employed in the
conditioning regimens prior to hematopoietic stem cell transplanta-
tion have a considerable negative effect on the oral epithelium. De-
pending on the agents and doses administered, oral mucositis can
range from mild to life threatening. The consequences of this
mucositis, depending on its degree, can impact a patients ability to
maintain oral hydration, nutrition and intake of medications. Addi-
tionally, the potential for local and systemic infections increases dra-
matically with the loss of the natural mucosal barrier. Many
interventions have been tried over the years to lessen the degree of
mucositis and all have met with mixed, inconsistent results. The re-
cent introduction of a new agent, CaphosolR, has added to the list of
potential treatments. One conditioning protocol that has consis-
tently produced varying degrees of mucositis in our patients is the
BEAM regimen. It consists of carmustine, etoposide, cytarabine
and melphalan given intravenously over a 6 day period and is widely
used in the non-Hodgkins lymphoma population. Previous attempts
to modify the mucositis have been met with marginal success so it
was decided to trial CaphosolR in this setting. CaphosolR was pre-
pared according to the manufacturers instructions and administered
4 times daily to 9 patients receiving the BEAM regimen. This group
was compared to 13 patients that received BEAM in the previous 6
months who did not get CaphosolR. Some degree of mucositis was
seen in all the patients which required narcotic analgesic interven-
tion. Themost severe cases required the use of patient controlled an-
algesia (PCA) with either morphine or hydromorphone. We found
that four (4) patients in each group needed PCA however the Capho-
solR group needed a mean of only 4.25 days of PCA therapy vs 5.5
days in the other group and the overall patient pain rating was less
in the CaphosolR population. We also found that the length of
stay after transplantation (LOS) was 1.5 days less in the CaphosolR
group (14.5 vs 15.9 days) while the mean number of days on Capho-
solR was 10.2. It was felt that the treatment had a positive effect on
patient outcome and quality of life and it is now used in all patients
receiving BEAM therapy. We continue to evaluate it in this group
along with other transplant populations, non-transplant chemother-
apy patients and those receiving radiotherapy for head/neck cancer.439
ATTENUATED KERATINOCYTE GROWTH FACTOR AND ETOPOSIDE
BASED CONDITIONING FOR ALLOGENEIC TRANSPLANT
Booth, D.L. Royal Melbourne Hospital, Melbourne, Victoria, Australia
Objective:Assess the impact of keratinocyte growth factor (KGF)
administered prior to conditioning only, on oral mucositis in alloge-
neic transplant recipients receiving etoposide based conditioning.
Method: All patients scheduled for HSCT with TBI/ Etoposide
or Bu/Cy/Etoposide from June 2006 to August 2008 were offered
KGF at 60 mcg/kg on 3 consecutive days finishing 24 hours prior
to conditioning. Work previously done in our institution showed
KGF was not beneficial in allogeneic patients receiving myeloabla-
tive conditioning regimens. This result was attributed to scheduling
of post conditioning KGF and short course methotrexate despite
omission of day11 KGF to avoid coadministration within 24 hours.
Therefore, in this cohort of patients post conditioning KGF doses
were omitted completely. WHO oral mucositis score, duration,
TPN and analgesia usage were recorded prospectively.
Results: Twelve patients (8 allogeneic, 4 MUDs, 7 B-ALL, 2
Ph1ve ALL, 2 T-ALL, 1 biphenotypic leukaemia) consented toKGF. Conditioning was TBI/etoposide in 10 patients TBI/thymo-
globulin/etoposide in 1 patient and Bu/Cy/etoposide in 1 patient
with CSA and MTX on days 1, 3, 6 and 11 as GVHD prophylaxis.
Grade 3 to 4 mucositis was experienced by 8/12 patients (67%) com-
pared to 36/38 (95%) of TBI etoposide patients prior to June 2006
(P 5 0.024). Mean duration of TPN was 13.5 days compared to
18 days and mean duration of opiate analgesia was 11.5 days
compared 14.5 days for KGF cohort and the historical cohort
respectively.
Conclusions: Attenuated KGF is effective for amelioration of
oral mucositis associated with etoposide containing conditioning
in allogeneic transplants.440
A RAPID NANOPARTICLE IMMUNOASSAY TO QUANTITATE BUSULFAN IN
PLASMA
Salamone, S.J.1, Benfield, C.N.1, Courtney, J.B.1, Harney, R.L.1,
Kozo, D.R.1, Li, Y.1, Lundell, G.D.1, Shaw, L.M.2, Gardiner, J.A.M.2
1 Saladax Biomedical Inc, Bethlehem, PA; 2 University of Pennsylvania
Medical Center, Philadelphia, PA
Background: Busulfan (BU), a bifunctional alkylating agent, is
the most widely used chemotherapeutic agent as a component of
high-dose conditioning regimens for hematopoietic stem cell trans-
plantation (HSCT). Studies have shown that maintaining a targeted
exposure [expressed as area under the time-curve (AUC)] throughout
the complete regimen is essential for successful engraftment,
reduced risk of graft vs. host disease or venoocclusive disease. For
optimal therapeutic drug management (TDM), an assay that can
deliver rapid high quality results would be desirable.
Methods: Monoclonal antibodies bound to nanoparticles were
used to develop an immunoassay for the Roche c111 chemistry
analyzer. The assay was monitored at 629 nm and quantitated with
a stabilized calibrator of busulfan. Assay precision, linearity, calibra-
tion stability and limit of detection (LoD) were determined. Clinical
samples were analyzed and correlated with GC-MS.
Results:With six calibrators from0–2,000 ng/mL, a stabilized bu-
sulfan derivative, and auto-dilution, plasma samples with concentra-
tions up to 10,000 ng/mL could be determined. Time-to-first-result
was 12 min and 25 samples/h could be measured from a stored stan-
dard curve. Imprecision across the range of assay was\7% and the
assaywas linear upondilutionover the entire range.Cross-reactivities
for sulfolane, tetrathiophene and 3-hydroxsulfolane were\1%. The
LoDwas 50 ng/mLwith a functional sensitivity of 100 ng/mL. Assay
results of clinical samples (237 to 1,711ng/mL) correlated well with
GC-MS results: (R. 0.98, slope 1.05, intercept5 39 ng/mL).
Conclusions: This immunoassay is suitable for determining bu-
sulfan concentrations in plasma. It offers advantages of turn-around
time, small sample size, no sample pre-treatment and a stable calibra-
tor that can be stored at room temperature. Automation and rapid
turn-around time with a small benchtop analyzer enable efficient
routine monitoring of busulfan concentrations in clinical practice
which can lead to better patient care.441
PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL
BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA
(AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
Hutcherson, D.A.1, Surati, M.1, Sanvidge, K.1, Harvey, D.2, Al-
Baldawi, R.N.3, Langston, A.2, Flowers, C.2, Lonial, S.2, Kaufman, J.2,
Lechowicz, M.J.2, Waller, E.2 1 Emory Healthcare, Atlanta, GA; 2 Emory
University, Atlanta, GA; 3 Mercer University, Atlanta, GA
Background: Busulfan (Bu) and cyclophosphamide are widely
used in conditioning regimens before hematopoietic cell transplan-
tation. Increased relapse rates and graft rejection have previously
been reported with low Bu area-under-the-curve (AUC) micromol*
min/L, and sinusoidal obstruction syndrome is associated with high
AUCs.This has lead to strategies to adjust Bu dosing to achieve a tar-
get AUC. Previous studies have suggested that a 0.8 mg/kg dose of
IV Bu would achieve an AUC similar to that of 1 mg/kg of oral
Bu. PK monitoring of IV Bu at our institution demonstrated that
